Wilms 肿瘤基因 1（WT1）是高级别子宫肉瘤的预后标志物。

Wilms tumor gene 1 (WT1) is a prognostic marker in high-grade uterine sarcoma.

机构信息

Laboratory of Experimental Gynecology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium.

出版信息

Int J Gynecol Cancer. 2011 Feb;21(2):302-8. doi: 10.1097/IGC.0b013e318207cab5.

DOI:10.1097/IGC.0b013e318207cab5

PMID:21734473

Abstract

INTRODUCTION

Wilms tumor gene 1 (WT1) contributes to uterine sarcoma tumor biology. In this study, we aimed to clarify the prognostic value of WT1.

METHODS

A retrospective clinical and histopathological review of 71 women with high-grade uterine sarcoma (leiomyosarcoma [n = 24], undifferentiated sarcoma [n = 9]), and carcinosarcoma (n = 38) was performed. Patients were followed up for at least 12 months. Wilms tumor gene 1 expression was determined by immunohistochemistry. Data on recurrence (progression-free survival) and overall survival (OS) were available for all patients. Univariate and multivariate analyses of WT1 expression were carried out using Kaplan-Meier curves and Cox regression, respectively.

RESULTS

Forty-nine (69%) tumors were WT1 positive. Forty-seven (66%) patients died of the disease, with a median OS time of 22 months. Wilms tumor gene 1 was a predictor of survival in the univariate analysis: the hazard ratio of WT1 positivity was 2.44 (95% confidence interval, 1.34-4.71) for progression-free survival and 2.48 (95% confidence interval, 1.26-4.90) for OS. Multivariate analysis including stage, age, tumor size, and sarcoma subtype identified only stage and WT1 positivity as independent prognostic markers for survival.

CONCLUSIONS

The identification of WT1 as a prognostic marker confirms its role in high-grade uterine sarcoma and carcinosarcoma tumor biology.

摘要

简介

Wilms 肿瘤基因 1（WT1）有助于子宫肉瘤肿瘤生物学。在这项研究中，我们旨在阐明 WT1 的预后价值。

方法

对 71 名患有高级别子宫肉瘤（平滑肌肉瘤[n=24]、未分化肉瘤[n=9]）和癌肉瘤（n=38）的女性患者进行了回顾性临床和组织病理学检查。患者至少随访 12 个月。通过免疫组织化学测定 WT1 表达。所有患者均有复发（无进展生存期）和总生存期（OS）的数据。使用 Kaplan-Meier 曲线和 Cox 回归分别对 WT1 表达进行单因素和多因素分析。

结果

49 例（69%）肿瘤 WT1 阳性。47 例（66%）患者死于该疾病，中位 OS 时间为 22 个月。WT1 在单因素分析中是生存的预测因子：WT1 阳性的风险比为 2.44（95%置信区间，1.34-4.71），用于无进展生存期，风险比为 2.48（95%置信区间，1.26-4.90），用于 OS。包括分期、年龄、肿瘤大小和肉瘤亚型在内的多因素分析仅确定分期和 WT1 阳性是生存的独立预后标志物。